Combining immune treatment and precision radiotherapy for lung cancer brain metastasis
Multi-omics Evaluation System and Preferred Mode of Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy
This study is testing a new way to treat lung cancer that has spread to the brain by combining immune therapy with targeted radiation to see if it helps patients feel better.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hunan Province Tumor Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT05584267 on ClinicalTrials.gov |
What this trial studies
This clinical trial is a prospective multicenter study aimed at developing a decision-making system for treating lung cancer with brain metastases. It combines immunotherapy with large-segmentation precision radiotherapy, utilizing imagomics, clinicopathological features, and molecular pathological features to enhance treatment outcomes. The study focuses on patients with confirmed non-small cell lung cancer who have asymptomatic brain metastases and meet specific eligibility criteria. The approach seeks to optimize treatment strategies for this challenging condition.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with confirmed non-small cell lung cancer and asymptomatic brain metastases.
Not a fit: Patients with contraindications to chemotherapy or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with brain metastases from lung cancer.
How similar studies have performed: Other studies have shown promise in combining immunotherapy with radiotherapy for various cancers, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years of age on day of signing informed consent * Histopathology confirmed non-small cell lung cancer * Asymptomatic brain metastases * EGFR/ALK ROS1 driver gene mutation negative * RECIST 1.1 based available assessment of lesions * ECOG 0-1 * Brain metastases 1-4 * Single lesion ≤4cm Exclusion Criteria: * Patients with contraindication of chemotherapy Pregnant or breast feeding women
Where this trial is running
Changsha, Hunan
- Hunan Cancer Hospital — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Yongchang C Zhang, MD
- Email: zhangyongchang@csu.edu.cn
- Phone: +8613873123436
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.